Spexis announces sale of preclinical antibiotics program to Basilea.

Swiss biopharmaceutical company Spexis has announced the sale of its preclinical antibiotics program to Basilea. The program consists of novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains. Preclinical studies have shown the antibiotics to exhibit bactericidal activity against a broad range of Gram-negative bacteria both in vitro and in vivo. Basilea will pay up to CHF 2 million for the program, which is part of Spexis' efforts to partner or divest non-core programs and assets as the company remains under a moratorium.

January 15, 2024
5 Articles

Further Reading